Format

Send to

Choose Destination
Lancet Diabetes Endocrinol. 2016 Feb;4(2):98-9. doi: 10.1016/S2213-8587(15)00494-5.

Insulin patents and market exclusivities: unresolved issues--Authors' reply.

Author information

1
Program On Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. Electronic address: jluo1@partners.org.
2
Program On Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA.
PMID:
26825232
DOI:
10.1016/S2213-8587(15)00494-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center